The talk will draw on Ben’s broad experience in research and clinical work with psychedelics over the last 15 years. From early beginnings in childhood trauma and the psychological roots of addictions, through to contemporary studies with MDMA-assisted psychotherapy for alcohol use disorder.
Ben will highlight the recent psychedelic renaissance, and chart the opening of Awaken Life Sciences, the biotech company he has co-founded, to develop, research and deliver psychedelic medicines through opening multiple clinics in the UK and EU. Special attention will be paid to the developmental causes of addictions and trauma-related disorders, and the unique opportunity offered by psychedelic medicines, particularly MDMA, to offer a novel, safe and effective approach to these otherwise difficult to treat and lifelong mental disorders.
Dr Ben Sessa has been at the forefront of psychedelic research in the UK through his affiliations with Imperial College London. Ben qualified as a medical doctor from UCL in 1997 and went on to specialise in psychiatry. Ben started studying psychedelics as a junior doctor, and has taken part in research projects at Bristol University, Cardiff University and Imperial College London with LSD, psilocybin, DMT, ketamine and MDMA – receiving and/or administering all of these compounds in legal research settings.
Doors open 7 pm
Talk starts 7:30 pm
Q&A 9 pm
This is an 18+ event
Presented by @seedtalks